S'abonner

The estimation of diagnostic accuracy of tests for COVID-19: A scoping review - 31/10/20

Doi : 10.1016/j.jinf.2020.08.043 
Dierdre B. Axell-House a, Richa Lavingia b, c, d, Megan Rafferty c, d, Eva Clark a, e, E. Susan Amirian c, Elizabeth Y. Chiao f,
a Section of Infectious Diseases, Department of Internal Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA 
b Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA 
c School of Social Sciences, Rice University, MS 272, 5620 Greenbriar Dr, Houston, TX 77005, USA 
d UTHealth School of Public Health, Houston, TX, USA 
e Houston HSR&D IQuESt, Michael E. DeBakey VA Medical Center, 2450 Holcombe Blvd, Houston, TX, 77021, USA 
f Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1155 Pressler St., Unit 1340, Houston, TX 77030, USA 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Highlights

SARS-CoV-2 tests in the studies in this scoping review are lacking rigorous evaluationnecessary for standard FDA approval due to the emergency state generated by the COVID-19 pandemic.
Reports of performance test characteristics in the literature should be interpreted carefully given the heterogeneity among available studies in terms of test types, reference standards, metrics, and details of study design and methodology.
Future studies would benefit from employing statistical methods such as latent class analysis and other methods referenced above to accurately analyze their data.
Ensuring that national requirements for test performance analysis and reporting on diagnostic tests, perhaps based on the existing FDA guidelines, particularly as commercialization of these tests move forward would help ensure the appropriate settings for test utilization (i.e. individual asymptomatic screening, pool community screening, surveillance testing, or diagnostic testing).

Le texte complet de cet article est disponible en PDF.

Summary

Objectives

To assess the methodologies used in the estimation of diagnostic accuracy of SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) and other nucleic acid amplification tests (NAATs) and to evaluate the quality and reliability of the studies employing those methods.

Methods

We conducted a systematic search of English-language articles published December 31, 2019-June 19, 2020. Studies of any design that performed tests on ≥10 patients and reported or inferred correlative statistics were included. Studies were evaluated using elements of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) guidelines.

Results

We conducted a narrative and tabular synthesis of studies organized by their reference standard strategy or comparative agreement method, resulting in six categorizations. Critical study details were frequently unreported, including the mechanism for patient/sample selection and researcher blinding to results, which lead to concern for bias.

Conclusions

Current studies estimating test performance characteristics have imperfect study design and statistical methods for the estimation of test performance characteristics of SARS-CoV-2 tests. The included studies employ heterogeneous methods and overall have an increased risk of bias. Employing standardized guidelines for study designs and statistical methods will improve the process for developing and validating rRT-PCR and NAAT for the diagnosis of COVID-19.

Le texte complet de cet article est disponible en PDF.

Keywords : SARS-CoV-2, COVID-19, Diagnostic accuracy, Sensitivity, Specificity, QUADAS-2


Plan


© 2020  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 81 - N° 5

P. 681-697 - novembre 2020 Retour au numéro
Article précédent Article précédent
  • Editorial Board
| Article suivant Article suivant
  • Meningococcal disease surveillance in the Asia–Pacific region (2020): The global meningococcal initiative
  • Aye Mya Min Aye, Xilian Bai, Ray Borrow, Sotharith Bory, Josefina Carlos, Dominique A. Caugant, Chien-Shun Chiou, Vo Thi Trang Dai, Ener Cagri Dinleyici, Prakash Ghimire, Setyo Handryastuti, Jung Yeon Heo, Amy Jennison, Hajime Kamiya, Loong Tonnii Sia, Jay Lucidarme, Helen Marshall, Nina Dwi Putri, Senjuti Saha, Zhujun Shao, James Heng Chiak Sim, Vinny Smith, Muhamed-Kheir Taha, Phan Van Thanh, Usa Thisyakorn, Kinley Tshering, Julio Vázquez, Balaji Veeraraghavan, Saber Yezli, Bingqing Zhu

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.